Monogenic ALB Variants as Determinants of Severe Hypercholesterolemia: A Population-Based Cohort Study

Alexander S F Berry1, Dylan Cawley2, Andrea Hattenberger3

  • 1Department of Developmental Medicine, Geisinger, Lewisburg, Pennsylvania, USA.

Insights

Loss-of-function variants in the ALB gene are a new cause of high LDL-C, similar to familial hypercholesterolemia. These genetic changes in albumin significantly increase low-density lipoprotein cholesterol levels.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Biochemistry

Background:

  • Hypoalbuminemia is linked to myocardial infarction risk factors like hypercholesterolemia and diabetes.
  • Loss-of-function (LoF) variants in the ALB gene cause hypoalbuminemia.
  • Heterozygous ALB LoF variants increase low-density lipoprotein cholesterol (LDL-C), resembling familial hypercholesterolemia.

Purpose of the Study:

  • To investigate the impact of ALB LoF variants and other causes of low albumin on LDL-C levels.
  • Utilized data from two large population biobanks for comprehensive analysis.

Main Methods:

  • Employed data from Geisinger's MyCode and NIH's All of Us Research Program cohorts.
  • Adjusted LDL-C for lipid-lowering medication and extracted myocardial infarction diagnoses.
  • Calculated a polygenic score for serum albumin and used meta-analysis for results.

Main Results:

  • Among over 550,000 participants, 77 carried an ALB LoF variant.
  • ALB LoF variants reduced serum albumin by 0.69 g/dL and increased LDL-C by 38.3 mg/dL.
  • Paradoxically, polygenic determinants of lower albumin decreased LDL-C by 0.22 mg/dL per decile.

Conclusions:

  • ALB LoF variants are an underrecognized monogenic cause of elevated LDL-C.
  • The effect size of ALB LoF variants on LDL-C is comparable to familial hypercholesterolemia.
  • Distinct mechanisms underlie the divergent effects of ALB-mediated versus polygenic albumin reduction on LDL-C.
Abstract

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...